NCT05836584 2025-12-01
Testing Immunotherapy (Atezolizumab) With or Without Chemotherapy in Locoregional MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
Clinical Trials
7 trialsNCT00253370 2014-11-24
Sorafenib, Docetaxel, and Cisplatin in Treating Patients With Metastatic or Advanced Gastric or Gastroesophageal Junction Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00331682 2014-05-28
Docetaxel and Flavopiridol in Treating Patients With Refractory Metastatic Pancreatic Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00088933 2014-03-31
Vaccine Therapy and Sargramostim With or Without Docetaxel in Treating Patients With Metastatic Lung Cancer or Metastatic Colorectal Cancer
National Cancer Institute (NCI)
Phase 1 Terminated
NCT00978549 2013-08-07
Symptom Control With or Without Docetaxel in Treating Patients With Relapsed Esophageal Cancer or Stomach Cancer
National Cancer Institute (NCI)
Phase 3 Completed
NCT00003172 2013-06-21
Comparison of Combination Chemotherapy Regimens in Treating Patients With Advanced Stomach Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00075465 2008-07-24
Docetaxel and Epirubicin as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Adenocarcinoma of the Stomach
National Cancer Institute (NCI)
Phase 2 Unknown